We are entering a new world of very effective, but very expensive, drug treatments for rare disease. How should society think about pricing these treatments? Are there financial models that can help spread the costs and make them more affordable? And what does this suggest for a new role for government-financed Research and Development?
Principal Investigator Ju Li
Principal Investigator Peter So
Principal Investigator Susan Silbey
Principal Investigators Angela Koehler , Iain Cheeseman , Katharina Ribbeck
Principal Investigator Robert Macfarlane
Principal Investigator Evan Ziporyn
Principal Investigator Donald Lessard
Principal Investigators Christine Walley , Malick Ghachem , Kate Brown , Megan Black